Back to top

crispr: Archive

Zacks Equity Research

Intellia (NTLA) Depreciates 27% Over a Month: Here's Why

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

REGNPositive Net Change BDSIPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

REGNPositive Net Change VRTXPositive Net Change BDSIPositive Net Change NTLAPositive Net Change